Sökning: "minimal residual disease"

Visar resultat 1 - 5 av 33 avhandlingar innehållade orden minimal residual disease.

  1. 1. Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia

    Författare :Ingrid Thörn; Christer Sundström; Richard Rosenquist; Gisela Barbany; Johan Botling; Kjeld Schmiegelow; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Childhood acute lymphoblastic leukemia; minimal residual disease; IG TCR gene rearrangements; BCR-ABL1 fusion gene transcripts; real-time quantitative PCR; multicolor flow cytometry; Pathology; Patologi; Pathology; patologi;

    Sammanfattning : Traditionally, response to treatment in hematological malignancies is evaluated by light microscopy of bone marrow (BM) smears, but due to more effective therapies more sensitive methods are needed. Today, detection of minimal residual disease (MRD) using immunological and molecular techniques can be 100 times more sensitive than morphology. LÄS MER

  2. 2. Next Generation Sequencing for Measurable Residual Disease Detection in Acute Myeloid Leukemia

    Författare :Erik Delsing Malmberg; Göteborgs universitet; Göteborgs universitet; Gothenburg University; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; acute myeloid leukemia; minimal residual disease; massively parallel sequencing; next generation sequencing; NPM1; alloHCT;

    Sammanfattning : Acute myeloid leukemia (AML) is the most common form of acute leukemia and generally associated with a poor prognosis. For both children and adults, the treatment is based on chemotherapy. Allogeneic hematopoietic stem cell transplant (alloHCT) is reserved for patients with intermediate or high risk of relapse, due to its associated risks. LÄS MER

  3. 3. Multiparameter flow cytometry and minimal residual disease in patients with acute leukemia

    Författare :Elisabet Björklund; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; Flow cytometry; immunophenotyping; Minimal Residual Disease; acute leukemia; hernatopoietic stem cells;

    Sammanfattning : The investigation of minimal residual disease (MRD) with multiparameter flow cytometry (FC) immunophenotyping has proven to be a powerful approach for disease monitoring in patients with acute leukemia (AL). This technique mainly relies on the identification of minor leukemic cell populations that can be discriminated from their normal counterparts on the basis of phenotypic aberrancies observed at diagnosis. LÄS MER

  4. 4. The methodology and significance of minimal residual disease detection after allogeneic stem cell transplantation

    Författare :Mehmet Uzunel; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; Minimal Residual Disease; Stem Cell Transplantation; ALL; AML; CML; Relapse;

    Sammanfattning : Allogeneic stem cell transplantation (SCT) is the choice of therapy for leukemia patients who respond poorly to conventional chemotherapy. Despite high remission rates after SCT, relapse of the underlying disease remains one of the most frequent causes of treatment failure. LÄS MER

  5. 5. Detection of immunoglobulin heavy chain gene rearrangement with PCR for MRD analysis in lymphoproliferative disorders

    Författare :Ulf Thunberg; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Genetics; Minimal residual disease; Immunoglobulin gene rearrangement; PCR; Leukemia; Lymphoma; Myeloma; Genetik; Clinical genetics; Klinisk genetik; Pathology; patologi;

    Sammanfattning : Immunoglobulin heavy chain (IGH) gene rearrangement occurs during early B-lymphocyte differentiation, assembling the different IGH gene segments to a functional gene, which can serve as a marker for study of lineage association and detection of Minimal Residual Disease (MRD) in clonal diseases deriving from B-lymphocytes or their early differentiation stages. Use of a molecular marker for the leukemic cells could help improve treatment by monitoring therapeutic efficacy, predicting relapse, and identifying very small amounts of tumour cells contaminating autografts after purging or enrichment of stem cells. LÄS MER